| Literature DB >> 24504149 |
Chia-Jie Lee1, Yhu-Chering Huang2, Shuan Yang3, Kuo-Chien Tsao3, Chih-Jung Chen2, Yu-Chia Hsieh2, Cheng-Hsun Chiu2, Tzou-Yien Lin2.
Abstract
BACKGROUND: Clinical features of coxsackievirus A4 (CA4), B3 (CB3) and B4 (CB4) infections in children have not been comprehensively described. METHODS/PRINCIPALEntities:
Mesh:
Year: 2014 PMID: 24504149 PMCID: PMC3913601 DOI: 10.1371/journal.pone.0087391
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow chart of the patients enrolled in this study.
CA4, coxsackievirus A4; CB3, coxsackievirus B3; CB4, coxsackievirus B4.
Figure 2Isolates and percentage of Coxsackie A4, B3 and B4 isolates from January, 2004 to June, 2012 in Chang Gung Memorial Hospital, Taiwan.
Figure 3Monthly distribution of coxsackievirus A4 (CA4), B3 (CB3) and B4 (CB4) isolates from January, 2004 to June, 2012 in Chang Gung Memorial Hospital, Taiwan.
Demographics of 386 children with Coxsackievirus A4, B3 and B4 infections in Chang Gung Memorial Hospital, January, 2004–June, 2012.
| Characteristics | No. (%) |
| |||
| Coxsackie A4 | Coxsackie B3 | Coxsackie B4 | Total | ||
|
| 158 | 145 | 83 | 386 | |
| Male gender | 81 (51.3) | 88 (60.7) | 49 (59) | 218 (56.5) | .222 |
| Age, months(median [IQR]) | 30.5 [17.8, 48] | 11 [1.2, 33.5] | 35 [12, 56] | 25 [10,49] | .000 |
| ≦3 years | 92 (58.2) | 111 (76.6) | 42 (50.6) | 245 (63.5) | .000 |
| ≦3 months | 1 (0.63) | 59 (40.7) | 13 (15.7) | 73(18.9) | .000 |
| Admission rate (%) | 65.2 | 90.3 | 74.7 | 76.7 | .000 |
| Specimens | |||||
| Throat | 158 | 128 | 81 | 367 | |
| Rectum | 0 | 60 | 8 | 68 | |
| Cerebrospinal fluid | 0 | 30 | 0 | 30 | |
| Others | 0 | 1 | 1 | 2 | |
| Multiple sites (≥2 sites) | 0 | 52 | 7 | 59 | |
|
| 103 | 131 | 62 | 296 | |
| Male gender | 54(52.4) | 78(59.5) | 38(45.8) | 170(57.4) | .434 |
| Age, months(median [IQR]) | 27 [15, 45] | 8 [0.9, 32] | 24 [7, 53.3] | 21 [5,46] | .001 |
| ≦3 years | 69(67) | 105(80.2) | 39(62.9) | 213(72) | .017 |
| ≦3 months | 1(1) | 59(45) | 12(19.3) | 72(24.7) | .000 |
| Days of hospital stay (median [IQR]) | 4 | 6 | 5 | 5 | .000 |
| Underlying diseases | 11(10.7) | 22(16.8) | 12(19.4) | 45(15.2) | .257 |
| Prematurity | 3 | 13 | 6 | 22 | |
| Allergy | 2 | 4 | 1 | 7 | |
| Neurological | 3 | 5 | 1 | 9 | |
| Congenital anomaly | 1 | 2 | 2 | 5 | |
| Others | 0 | 1 | 2 | 3 | |
Culture from urine.
Culture from pleural effusion.
Clinical manifestations in 296 hospitalized children with coxsackievirus A4, B3 and B4 infections stratified by serotypes.
| Symptoms and signs | No. (%) |
| ||
| Coxsackie A4(n = 103) | Coxsackie B3(n = 131) | Coxsackie B4(n = 62) | ||
|
| ||||
| Fever | 102 (99) | 126 (96.2) | 61 (98.4) | .330 |
| High fever (>39°C) | 74 (75.5) | 65 (55.1) | 32 (57.1) | .011 |
| Days of fever (median [IQR]) | 3 | 4 | 4 | .001 |
| Fever>3 days | 23 (23.5) | 65 (55.1) | 28 (50.9) | .000 |
| Poor oral intake | 89 (86.4) | 65 (49.6) | 34 (54.8) | .000 |
| Poor activity | 56 (54.3) | 61 (46.6) | 26 (41.9) | .261 |
|
| ||||
| Oral ulcer | 83 (80.6) | 29 (22.1) | 25 (40.3) | .000 |
| Skin rash | 11 (10.7) | 4 (3.1) | 3 (4.8) | .039 |
|
| ||||
| Cough | 51 (49.5) | 43 (32.8) | 28 (45.1) | .028 |
| Rhinorrhea | 38 (36.9) | 25 (19.1) | 20 (32.2) | .008 |
|
| ||||
| Diarrhea | 17 (16.5) | 12 (9.2) | 11 (17.7) | .145 |
| Vomiting | 27 (26.2) | 27 (20.6) | 20 (32.2) | .205 |
|
| ||||
| Myoclonic jerk | 11 (10.7) | 13 (9.9) | 8 (12.9) | .823 |
| Headache | 2 (1.9) | 10 (7.6) | 5 (8.1) | .121 |
| Limb weakness | 0 (0) | 0 (0) | 1 (1.6) | .151 |
| Febrile seizure | 3 (2.9) | 4 (3.1) | 3 (4.8) | .773 |
| Afebrile seizure | 2 (1.9) | 7 (5.3) | 1 (1.6) | .247 |
Fever was defined as body temperature greater than 38°C.
Typical mucocutaneous manifestations of enteroviral infections.
Laboratory findings in 296 hospitalized children with Coxsackievirus A4, B3 and B4 infections stratified by serotypes.
| Laboratory data | No. (%) |
| |||
| Coxsackie A4(n = 103) | Coxsackie B3(n = 131) | Coxsackie B4(n = 62) | |||
|
| |||||
| WBC (×1000/µL) on admission | 13.9±6.1 | 11.3±4.0 | 12.4±5.3 | .000 | |
| Leukocytosis (peak) | 35 (34) | 21 (16) | 18 (29) | .000 | |
| Leukopenia (nadir) | 2 (2) | 2 (1.5) | 1 (1.61) | .745 | |
| Hb (g/dL) on admission | 11.8±1.2 | 12.1±2.1 | 11.8±1.4 | .273 | |
| Hb<10 g/dL (nadir) | 5 (4.9) | 29 (22.3) | 6 (9.7) | .003 | |
| Platelet (1000/µL) on admission | 262.1±70.4 | 299.2±140.5 | 312.0±127.0 | .014 | |
| Platelet<150000/µL (nadir) | 0 (0) | 16 (12.3) | 4 (6.5) | .007 | |
| CRP (mg/L) on admission | 40.5±37.0 | 20.6±25.9 | 30.1±53.5 | .000 | |
| CRP>40 mg/L(peak) | 41 (40.6) | 22 (16.9) | 12 (20) | .000 | |
|
| |||||
|
| 0 | 35 | 0 | ||
| Pleocytosis | 31 | ||||
| WBC (/µL) | – | 170±193 | – | ||
| Neutrophil (%) | – | 17.7±27.7 | – | ||
| Lymphocyte (%) | – | 18.6±21.4 | – | ||
| Protein (mg/dL) | – | 93.9±51.8 | – | ||
| Sugar (mg/dL) | – | 48.5±10.5 | – | ||
| Lactate (mg/dL) | – | 17.1±4.2 | – | ||
| Positive virus culture | – | 29 | – | ||
Leukocytosis was defined as WBC count ≥15000/µL in patients older than 1-month-old and ≥30000/µL in patients young than 1-month-old.
Leukopenia was defined as WBC count <4500/µL.
Pleocytosis was defined as WBC count in CSF greater than 30 cells/mm3 in neonates or greater than 5 cells/mm3 beyond the neonatal age.
Diagnosis, treatment, complications and outcomes of 296 hospitalized children with coxsackievirus A4, B3 and B4 infections stratified by serotypes.
| Clinical parameters | No. (%) |
| ||
| Coxsackie A4 (n = 103) | Coxsackie B3 (n = 131) | Coxsackie B4 (n = 62) | ||
|
| ||||
| Herpangina | 77 (74.8) | 22 (16.8) | 20 (32.3) | .000 |
| Hand-foot-mouth disease | 5 (4.9) | 2 (1.5) | 2 (3.2) | .337 |
| Tonsillitis/pharyngitis | 14 (13.6) | 18 (13.7) | 17 (27.4) | .035 |
| LRTI | 11 (10.7) | 17 (13) | 10 (16.1) | .552 |
| Acute gastroenteritis | 2 (1.9) | 5 (3.8) | 11 (17.7) | .000 |
| Young infant with fever | 0 (0) | 31 (23.7) | 9 (14.5) | .000 |
| Aseptic meningitis | 0 (0) | 35 (26.7) | 0 (0) | .000 |
| Meningismus | 1 (1) | 7 (5.3) | 3 (4.8) | .585 |
| Encephalitis | 0 (0) | 6 (4.6) | 0 (0) | .021 |
| Others | 8 (7.8) | 9 (6.9) | 5 (8.1) | .945 |
| More than one diagnosis | 14 (13.6) | 18 (13.7) | 14 (22.6) | |
|
| ||||
| Antibiotics | 19 (18.4) | 77 (58.8) | 28 (45.2) | .000 |
| IVIG | 2 (1.9) | 14 (10.7) | 2 (3.2) | .012 |
|
| 1 (1) | 12 (9.2) | 0 (0) | |
| DIC | 1 (1) | 9 (6.9) | 0 (0) | .012 |
| Myocarditis | 1 (1) | 1 (0.8) | 0 (0) | .752 |
| Respiratory distress | 1 (1) | 7 (5.3) | 0 (0) | .041 |
| Shock | 1 (1) | 6 (4.6) | 0 (0) | .076 |
| HNC | 0 (0) | 6 (4.6) | 0 (0) | .013 |
| Other | 0 (0) | 3 (2.3) | 0 (0) | .148 |
|
| ||||
| Total recovery | 102 (99) | 121 (92.4) | 62 (100) | .006 |
| Long-term sequelae | 1 (1) | 10 (7.6) | 0 (0) | .006 |
| Mortality | 1 (1) | 1 (0.8) | 0 (0) | .752 |
| Requiring ECMO | 1 (1) | 1 (0.8) | 0 (0) | .752 |
URTI, upper respiratory tract infection; LRTI, lower respiratory tract infection; IVIG, intravenous immunoglobulin; DIC, disseminated intravascular coagulopathy; HNC, hepatic necrosis and coagulopathy; ECMO, extracorporeal membrane oxygenation.
Two patients complicated with renal failure and one patient had rhabdomyolysis.
Chest X ray findings and results of etiology survey in hospitalized lower respiratory tract infection (LRTI) patients.
| No. (%) |
| |||
| Coxsackie A4 | Coxsackie B3 | Coxsackie B4 | ||
|
| 11 | 17 | 10 | .552 |
|
| ||||
| Increased perihilar infiltrates | 10 (90.9) | 16 (94.1) | 8 (80) | |
| Patch consolidation | 1 (9.1) | 1 (5.9) | 1 (10) | |
| Pleural effusion | 0 (0) | 0 (0) | 1 (10) | |
|
| ||||
| Positive urine pneumococcus antigen | 0 (0) | 0 (0) | 1 (33.3) | |
| Mycoplasma pneumoniae | 0 (0) | 2 (33.3) | 1 (20) | |
| MRSA | 0 (0) | 2 (100) | 0 (0) | |
| RSV antigen (NP) | 0 (0) | 0 (0) | 0 (0) | |
Including mycoplasma serology or mycoplasma DNA PCR.
MRSA, methicillin-resistant Staphylococcus aureus; confirmed by sputum culture.
RSV, respiratory syncytial virus; nasopharyngeal aspirate examined by immunofluorescent aassay.